Literature DB >> 272945

Vincristine, prednisone and L-asparaginase in the induction of remission in children with acute lymphoblastic leukemia following relapse.

F H Kung, W L Nythan, J Cuttner, G Falkson, P Lanzkowsky, V Del Duca, I U Nawabi, K Koch, H Pluess, A Freeman, E O Burgert, L A Leone, F Ruymann, R B Patterson, T Degnan, N Hakami, T F Pajak, J Holland.   

Abstract

Two hundred and twenty-seven children with recurrent acute lymphoblastic leukemia were treated with various combinations of vincristine, prednisone, cyclophosphamide and L-asparaginase in an approach to the induction of remission. The combination of L-asparaginase 1,000 mu/kg iv q.d. x 10, vincristine 2.0 mg/m2iv q.w. x 4 and prednisone 40 mg/m2 p.o.q.d. x 28 days was found to be highly effective. The incidence of remission was 73%. No significant improvement was achieved when cyclophosphamide was added to this regimen. Various combinations of cytosine arabinoside, cyclophosphamide, vincristine, prednisone, BCNU or CCNU failed to maintain remission duration for more than two or three months. Neither BCNU nor CCNU prevented the development of CNS leukemia.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 272945     DOI: 10.1002/1097-0142(197802)41:2<428::aid-cncr2820410208>3.0.co;2-c

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  Second remissions in childhood acute lymphoblastic leukaemia.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1981-03-07

2.  Bone marrow transplantation in Canada.

Authors:  N A Buskard
Journal:  Can Med Assoc J       Date:  1980-07-05       Impact factor: 8.262

3.  Development of a mini-tablet of co-grinded prednisone-Neusilin complex for pediatric use.

Authors:  H Lou; M Liu; L Wang; S R Mishra; W Qu; J Johnson; E Brunson; H Almoazen
Journal:  AAPS PharmSciTech       Date:  2013-06-13       Impact factor: 3.246

4.  Vindesine, prednisone, and daunomycin in acute lymphoblastic leukemia in relapse.

Authors:  G Garay; J Milone; E Dibar; S Pavlovsky; R Kvicala; F Sackmann Muriel; D Montres Varela; M Eppinger-Helft
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

5.  CCNU in combination chemotherapy for advanced histologically unfavorable non-Hodgkin's lymphoma.

Authors:  D V Jackson; H B Muss; F Richards; D R White; C L Spurr; M R Cooper; R M Christian; T F Trahey; L D Case; H B Wells
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

6.  Marrow relapse on maintenance chemotherapy in childhood acute lymphoblastic leukaemia.

Authors:  P J Kearney; J H Baumer; B C Howlett
Journal:  Br J Cancer       Date:  1979-12       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.